It continues to amaze us at the depth of ineptitude shown by the JDRF. Today they released the following statement;
“JDRF, the leading global organization funding type 1 diabetes (T1D) research, is announcing a new initiative that will support the development of open protocols for artificial pancreas (AP) technology.”
Now let’s be clear we’re all for open protocols but seriously isn’t this like locking the barn door after the cattle has escaped already. Yep just what we need after Johnson and Johnson (NYSE: JNJ) announces their decision to shut down Animas and Tandem (NASDAQ: TNDM) is on . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.